Jonathan J. Cherry Email & Phone Number

Us

Leading cross-functional teams responsible for clinical development, execution and successful delivery of pivotal trials for Friedreich’s Ataxia and Mitochondrial Disease with associated Seizures o Collaborating with senior leadership to define the immediate and long-term vision for the project teams, defining project goals, and the establishment and prioritization of the overall project timelines and deliverables o Working with the teams to define, develop and clearly articulate a range of strategic and tactical options that align with the corporate business objectives, budget, and resources.

Cambridge, Ma, Us

Program Director - SPINRAZA PDC

Cambridge, Ma, Us

Cambridge, Ma, Us

• Partner with both the Head of Research and the Head of BTMS to establish a cohesive approach for early discovery with a focus on preclinical portfolio programs and the internal capabilities and infrastructure needed to position Biogen as a world class research organization.• Focus on building better communication between Research and BTMS and with our partners across the organization• Help coordinate and the preclinical governance forum to enable effective decision making and ensure that the portfolio is aligned with R&D and corporate goals• Work closely with the Business Operations and Finance teams to match our resources with our goals and identify trade-offs when necessary

Cambridge, Ma, Us

•Collaborate with Research Unit Heads for Acute Neurology, Epilepsy, Pain, Ophthalmology, and Neurocognition to develop, manage, and communicate the portfolio strategy & pipeline from target validation through POC. •Responsible for driving pipeline growth through the proactive management of internal development programs as well as external collaborations & partnerships• Driving the pre-POC portfolio prioritization process and portfolio growth strategy in collaboration with disease area and functional area heads• Tracking and aligning resources to disease area and portfolio priorities in collaboration with the Business Operations and Finance teams• Leading the communication of disease area strategy, pipeline, and priorities within R&D in collaboration with the Communication team

•Established development programs for early stage assets, including milestone, budget, and timeline strategy to complete IND enabling studies•Identified, initiated, and managed collaborations with CROs and academic groups to execute on development programs•Served as research project leader for programs in portfolio•Supported target identification, new program review, and portfolio expansion

Cambridge, Massachusetts, Us

Head of Screening and Core Technologies (2016-2017)•Member of RaNA’s R&D leadership team.•Served as Functional Head of cross-discipline teams supporting, screening, next generation sequencing, iPSC and cell biology core, assay development, and gene editing.•Research Project Leader for the preclinical lead therapeutic programs for Spinal Muscular Atrophy and Friedreich’s Ataxia. •Provided leadership for external collaborations and interactions with patient advocacy groups.Group Leader for Assay Development and Screening (2015-2016)•Managed a team of PhD/non-PhD scientists in order to support target identification, hit validation, and the iPSC/cell biology core.•Served as core team member for each therapeutic program to advise on assay design and execution, to manage resourcing needs, and help establish cell-based assays for selecting and optimizing lead oligonucleotides that are suitable for in vivo studies. •Research project leader and scientific driver of the pre-clinical lead therapeutic programs for Spinal Muscular Atrophy and Friedreich’s Ataxia.

New York, New York, Us

•Lead Biologist for Spinal Muscular Atrophy programs– Utilize expertise in neurodegenerative disease to develop strategy for the SMA drug discovery program. Coordinate with DMPK, Drug Saftey, Medicinal Chemistry, Translational Biomarker, and Clinical colleagues to advance pre-clinical lead compounds.•Research Project Leader for Novel SMN2 Inducers program - Develop, optimize, and validate new approaches to identify novel small molecule to treat SMA.•External Liaison with Academic Collaborators - Maintain relationships with key opinion leaders to increase our understanding of biology and the mechanism of action of new therapeutic approaches. Establish and manage collaborations with leading academics to expand our capabilities and accelerate internal drug discovery programs.

Indianapolis, In, Us

•Study of SMN expression profiles in Spinal Muscular Atrophy. Pre-clinical lead compound validation and mechanism of action studies for novel compounds that increase SMN2 protein levels in cell culture and SMA mouse models.•Lead optimization small molecules that inhibit E6 function in vitro and in human cell cultures, induce p53 expression, and regulate cell proliferation in Human Papillomavirus positive cells.

Worcester, Ma, Us

• Research focus on the molecular basis of the neurodegenerative disease Spinal Muscular Atrophy.• Study of the role of the human papillomavirus E6 protein in the viral life cycle and oncogenic progression in cervical cancer.• In charge of development and validation of two novel assays for high throughput screens to discovery new therapeutics for the treatment of Spinal Muscular Atrophy, HPV infection, and cervical cancer.• Identified and confirmed novel compounds that modulate SMN2 protein levels in cell culture models and SMA mouse models.• Identified compounds that inhibit E6 function in vitro and in human cell cultures, induce p53 expression, and regulate cell proliferation in HPV positive cells.

Doctorate, Microbiology And Molecular Genetics

B.S., Molecular, Cellular, And Developmental Biology